NPI registry status
Active
2026 NPPES data Endocrinology, Diabetes & Metabolism Physician NPI 1386074292 M.D.
Verify on CMS → Karina Szczepanczyk, M.D.
Endocrinology, Diabetes & Metabolism Physician in Middletown, Connecticut.
This profile is drawn from the federal National Provider Identifier Registry (CMS NPPES), which lists more than 7 million U.S. healthcare providers - including 7,871 in Endocrinology, Diabetes & Metabolism Physician, and covers specialty classification, practice address, and Medicare Part D prescribing data when reported. According to CMS, every field reflects the provider's official federal registration, see our methodology.
Federal data, no proprietary rating.
We show these CMS records as-is - no composite score, no star rating, no editorial opinion layered on top.
Prescribing volume
2K
Medicare Part D claims · 410 beneficiaries · Endocrinology, Diabetes & Metabolism Physician avg: 3K
Generic prescribing
45%
generic claims · 48% brand-name · higher generic rates reduce patient out-of-pocket costs
MIPS score
97.3/100
▲ 14 pts above national avg 83.5 · Exceptional
Industry payments
$29.19
1 payments · CMS Open Payments (Sunshine Act)
Source: CMS Medicare Part D Prescriber Public Use File, 2023
What the federal data shows
Karina Szczepanczyk, M.D. reported a CMS MIPS final score of 97.3/100 - above the 83.5 national average - and filed 2,080 Medicare Part D claims in 2023.
- 97.3/100
- MIPS score · +14 vs avg
- 2K
- Part D claims, 2023
- 45%
- generic prescribing
- Likely
- board-certified (heuristic)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) - no proprietary rating or editorial opinion is applied.
Karina Szczepanczyk, M.D.'s MIPS score vs every measured U.S. clinician
CMS Merit-based Incentive Payment System (MIPS) final score, 2023, the federal quality measure. Clinicians whose score CMS assigned without scoring any category are excluded.
97 ≥ 84th percentile 84% of 454,083 measured providers are in lower value bands
Each bar is a band; taller bars hold more measured providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
The percentile is a conservative whole-score-point band: it counts only measured clinicians in lower score bands. A CMS MIPS metric is not a recommendation or a clinical-quality rating by PlainDoctor. See methodology § corpus placement.
Source CMS Merit-based Incentive Payment System (MIPS) · 2023
Where Karina Szczepanczyk, M.D. sits
This provider among endocrinology, diabetes & metabolism physician peers
Across the 2,341 endocrinology, diabetes & metabolism physician providers who report both Medicare Part D prescribing and a MIPS quality score, Karina Szczepanczyk, M.D. writes more Part D claims than 46% of them and scores higher on MIPS quality than 85% - placing this provider in the lower-volume, high-quality quadrant. Volume reflects patient-panel size and specialty, not quality; the two axes are independent.
Part D claim volume vs MIPS quality, by specialty percentile
Each dot is one endocrinology, diabetes & metabolism physician peer from a representative sample of 60; the gold marker is Karina Szczepanczyk, M.D.. Source: CMS Medicare Part D Prescriber data and the CMS Merit-based Incentive Payment System, 2023.
✓
Board certification likely (heuristic, not verified)
Karina Szczepanczyk, M.D. practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting + 1 hospital affiliation - signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about Karina Szczepanczyk, M.D.?
High performer (top quartile)Primary specialty
Endocrinology, Diabetes & Metabolism Physician
Medicare Part D claims
2,080 21% vs specialty avg
MIPS final score
97.3/100 13.8 pts vs avg
Specialty distribution in Connecticut
How Endocrinology, Diabetes & Metabolism Physician compares to other specialties among Connecticut providers
Medicare quality performance, MIPS
Karina Szczepanczyk, M.D.'s 2023 MIPS final score plotted against the Endocrinology, Diabetes & Metabolism Physician national average
- MIPS Final Score
- 97.3/100
- vs 83.5 national avg · 2023 performance year
MIPS final score (Endocrinology, Diabetes & Metabolism Physician) - 97.3/100 vs national avg 83.5
How MIPS and board certification work
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
Karina Szczepanczyk, M.D. appears in the CMS NPPES registry as an Endocrinology, Diabetes & Metabolism Physician provider holding M.D. credentials at 540 SAYBROOK RD STE 210, Middletown, CT, 06457, with a listed phone of (860) 358-2470. NPI 1386074292 was issued on 11/14/2013.
Medicare Part D records for calendar year 2023 show 2,080 prescription claims written by this provider, covering 410 Medicare beneficiaries and totaling roughly $1.2 million in drug spend, split 48% brand-name and 45% generic by claim count. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 97.3/100 for the 2023 performance year (Quality 81.7), compared with the 83.5 average among clinicians with a measured score.
Endocrinology, Diabetes & Metabolism Physician is a mid-sized specialty nationwide, with 7,871 enrolled providers across 54 states and an average of 2,639 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline.
Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist, always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1386074292 |
|---|---|
| Specialty | Endocrinology, Diabetes & Metabolism Physician |
| Credentials | M.D. |
| Gender | Female |
| NPI Issued | 11/14/2013 |
CMS Quality Score (MIPS)
Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.
97.2738
Final Score
Measured-score avg: 83.5
81.6843
Quality
100
Promoting Interoperability
Reporting: Alternative Payment Model
Hospital and facility affiliations
Facilities where Karina Szczepanczyk, M.D. bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" - a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.
Middlesex Hospital
★★★☆☆ 3/5
Middletown, CT
Acute Care Hospitals
CMS CCN: 070020
Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).
Industry payments received (2024) - CMS Open Payments transparency data
The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for Karina Szczepanczyk, M.D.. Source: openpaymentsdata.cms.gov.
Total received
$29
Largest payer
Radius Health, Inc.
Most common payment type
Food and Beverage
Industry payments are not necessarily indicators of bias, they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.
Brand vs generic prescribing mix · Above average
Karina Szczepanczyk, M.D. - brand share 48.0%
Endocrinology, Diabetes & Metabolism Physician average
48% brand-name claims vs 45% generic, on 2,080 2023 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
2,080
Total Claims
$1.2M
Total Drug Cost
410
Medicare Beneficiaries
Prescribing Breakdown
- 30-Day Fills
- 5,094
- Total Day Supply
- 151,437
- Brand vs Generic
- 48% brand / 45% generic
- Brand Drug Cost
- $1.2M
- Generic Drug Cost
- $44K
Patient Demographics
- Average Patient Age
- 70.6 years
- Avg HCC Risk Score
- 1.71
- Gender Split
- 66% female / 34% male
- Age Distribution
- <65: 71, 65-74: 194, 75-84: 117, 85+: 28
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
What Karina Szczepanczyk, M.D. prescribes most
Top Medicare Part D drugs by claim count, 2023
- Levothyroxine Sodium
Levothyroxine Sodium
316 claims
- Trulicity
Trulicity
168 claims
- Metformin Hcl Er
Metformin Hcl Er
146 claims
- Synthroid 105
Synthroid
105 claims
- Atorvastatin Calcium 94
Atorvastatin Calcium
94 claims
- Tresiba Flextouch … 58
Tresiba Flextouch U-100
58 claims
- Jardiance 56
Jardiance
56 claims
- Metformin Hcl 48
Metformin Hcl
48 claims
| Drug | Claims |
|---|---|
| Levothyroxine Sodium | 316 |
| Trulicity Dulaglutide | 168 |
| Metformin Hcl Er Metformin Hcl | 146 |
| Synthroid Levothyroxine Sodium | 105 |
| Atorvastatin Calcium | 94 |
| Tresiba Flextouch U-100 Insulin Degludec | 58 |
| Jardiance Empagliflozin | 56 |
| Metformin Hcl | 48 |
| Alendronate Sodium | 44 |
| Ozempic Semaglutide | 41 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
More Endocrinology, Diabetes & Metabolism Physician in CT →
All providers in Connecticut →
Compare specialties →
Endocrinology, Diabetes & Metabolism Physician Overview
How Karina Szczepanczyk, M.D. fits within the Endocrinology, Diabetes & Metabolism Physician landscape nationally.
7,871
Endocrinology, Diabetes & Metabolism Physician Providers in US
54
States with Endocrinology, Diabetes & Metabolism Physician
2,639
Avg Claims per Provider
Karina Szczepanczyk, M.D.'s 2,080 claims are below the specialty average of 2,639.
Nearby Endocrinology, Diabetes & Metabolism Physician Providers in Connecticut
Other clinicians with the same primary specialty enrolled in Connecticut, drawn from the same CMS NPPES roster as Szczepanczyk.
Dr. Fadi Al-Khayer
MD
Storrs, CT
Dr. Vivek Alaigh
MD
Stamford, CT
Dr. Kenda Alkwatli
MD
Wethersfield, CT
Dr. Ipek Alpertunga
MD
Hartford, CT
Dr. Helen Anaedo
M.D
Plainville, CT
Compare Endocrinology, Diabetes & Metabolism Physician nationally: see state-by-state distribution →
Before you book an appointment
Use this federal record as your verification checklist, not as a recommendation.
- Confirm the NPI record is current in the official CMS registry, providers update their own NPPES details, and moves can lag. Verify this NPI
- Check the active license and any disciplinary history with the Connecticut medical board, federal registration is not a license check. Credential verification guide
- Weigh a second option: compare this provider with a nearby Endocrinology, Diabetes & Metabolism Physician peer on Medicare volume and prescribing patterns. Compare providers
Medicare Part D and MIPS figures describe practice patterns in federal programs only, they are not quality ratings, and PlainDoctor does not rate, rank, or recommend providers.
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
How to Find a Doctor
Step-by-step guide to choosing a provider
Verify Credentials
Check NPI, board certification & license status
Medical Specialties Explained
Who treats what and how specialties differ
Understanding Medicare Claims Data
What prescribing data reveals about a provider
In-Network vs Out-of-Network
How insurance networks affect your costs
Telehealth Guide
Virtual care options and coverage in 2026
Explore Connecticut
Frequently Asked Questions
What is Karina Szczepanczyk, M.D.'s specialty? ▼
Karina Szczepanczyk, M.D. specializes in Endocrinology, Diabetes & Metabolism Physician and practices in Middletown, Connecticut. Credentials: M.D..
How much does Karina Szczepanczyk, M.D. prescribe under Medicare Part D? ▼
In 2023, Karina Szczepanczyk, M.D. wrote 2,080 Medicare Part D claims totaling $1.2M in drug costs for 410 beneficiaries.
What is Karina Szczepanczyk, M.D.'s Medicare quality score? ▼
Karina Szczepanczyk, M.D. has a CMS MIPS Final Score of 97.3/100 (Quality: 81.7). The average MIPS Final Score across the 454,083 clinicians with at least one published category score is 83.5; clinicians whose score CMS assigned without scoring any category are excluded from that average. Source: CMS Merit-based Incentive Payment System (MIPS) 2023.
Where is Karina Szczepanczyk, M.D. located? ▼
Karina Szczepanczyk, M.D. is located at 540 SAYBROOK RD STE 210, Middletown, CT, 06457. Phone: (860) 358-2470.
What is Karina Szczepanczyk, M.D.'s NPI number? ▼
Karina Szczepanczyk, M.D.'s National Provider Identifier (NPI) is 1386074292, issued on 11/14/2013.
Does Karina Szczepanczyk, M.D. prescribe more brand-name or generic drugs? ▼
Karina Szczepanczyk, M.D.'s prescribing is 48% brand-name and 45% generic drugs by claim count, with $1.2M in brand drug costs.
How many Endocrinology, Diabetes & Metabolism Physician providers are there in the US? ▼
There are 7,871 Endocrinology, Diabetes & Metabolism Physician providers across 54 states in the US. The average Endocrinology, Diabetes & Metabolism Physician provider writes 2,639 Medicare Part D claims per year.
What drugs does Karina Szczepanczyk, M.D. prescribe most often? ▼
Based on 2023 Medicare Part D data, Karina Szczepanczyk, M.D.'s most frequently prescribed drugs include Levothyroxine Sodium, Trulicity, Metformin Hcl Er. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does Karina Szczepanczyk, M.D. accept Medicare? ▼
Karina Szczepanczyk, M.D. appears in CMS Medicare data with 2,080 Part D claims and 410 Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify Karina Szczepanczyk, M.D.'s credentials? ▼
Karina Szczepanczyk, M.D.'s NPI is 1386074292 with credentials M.D.. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.
Data Sources
View source datasets and methodology notes
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Quality Performance
- CMS Merit-based Incentive Payment System (MIPS) - 2023 performance year.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology
Every figure on PlainDoctor is rendered directly from the federal CMS NPPES registry, Medicare Part D, MIPS, and Open Payments records, no number is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.